Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Puja P KhannaZsuzsanna H McMahanGary CutterJeff FosterJoshua MelnickSara JaafarStephanie BiggersA K M Fazlur RahmanHui-Chien KuoMichelle FeeseAlan KivitzCharles KingWilliam ShergyJeff KentPaul M PelosoMaria I DanilaKenneth G SaagPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
Our findings indicate that MMF therapy with pegloticase is well tolerated and shows a clinically meaningful improvement in targeted serum urate level of ≤6 mg/dl at 12 and 24 weeks. This study suggests an innovative approach to pegloticase therapy in gout.